ZJLD (06979) issued a profit warning with an expected profit attributable to shareholders of approximately 520 million to 580 million yuan in 2025, a year-on-year decrease of 56.1% to 60.6%.
Zhenjiu Lidu (06979) announced that the group is expected to achieve revenues of approximately RMB 35.5 billion to RMB 37.0 billion for the year ending on December 31, 2025, compared to revenues of approximately RMB 70.7 billion for the year ending on December 31, 2024, representing a year-on-year decrease of 47.7% to 49.8%.
ZJLD (06979) announced that the Group expects to achieve revenue of approximately RMB 3.55 billion to RMB 3.7 billion for the year ending December 31, 2025, compared to revenue of approximately RMB 7.07 billion for the year ending December 31, 2024, representing a year-on-year decrease of 47.7% to 49.8%.
The Group expects to achieve a profit attributable to equity shareholders of the Company of approximately RMB 520 million to RMB 580 million for the year ending December 31, 2025, compared to RMB 1.32 billion for the year ending December 31, 2024, representing a year-on-year decrease of 56.1% to 60.6%; and an adjusted net profit (non-International Financial Reporting Standards measurement) of approximately RMB 520 million to RMB 580 million for the year ending December 31, 2025, compared to approximately RMB 1.68 billion for the year ending December 31, 2024, representing a year-on-year decrease of 65.5% to 69.0%.
The decrease is primarily due to weakening market demand leading to a decrease in liquor consumption, especially in business and social banquets, as well as a decline in consumption for gifting purposes. This decrease is also partly due to the Company's measures to further reduce channel inventory in the second half of 2025.
Related Articles

G CHINA FIN (00431) intends to sell and Feng Limited.

US Stock Market Move | Performance outlook for 2026 falls short of expectations, Duolingo (DUOL.US) plunges over 26% in pre-market trading.

HENLIUS (02696): The phase II / III clinical study of HLX22 combined with HLX87 for first-line treatment of HER2-positive recurrent or metastatic breast cancer (BC) patients has completed the first patient dosing in China.
G CHINA FIN (00431) intends to sell and Feng Limited.

US Stock Market Move | Performance outlook for 2026 falls short of expectations, Duolingo (DUOL.US) plunges over 26% in pre-market trading.

HENLIUS (02696): The phase II / III clinical study of HLX22 combined with HLX87 for first-line treatment of HER2-positive recurrent or metastatic breast cancer (BC) patients has completed the first patient dosing in China.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


